ScreenerHero

BLRX BioLineRx Ltd.

NAS · US · Healthcare · Biotechnology · biolinerx.com
2.205USD-3.80%Mkt Cap: 10.98M $P/E: —

BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in gliobl…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap10.98M USD
Enterprise Value7.73M USD
Revenue (TTM)1.39M USD
Gross Profit950.00K USD
Net Income (TTM)-1.18M USD
Revenue/Share0.60 USD
Last Price2.205 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees20
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.91
PEG—
EV/EBITDA-0.64
EV/Revenue5.55
P/S8.20
P/B0.76
EPS (TTM)0.00
EPS (Forward)-2.52
52W Range
2.1502% of range4.560
52W High4.560 USD
52W Low2.150 USD
Profitability
Gross Margin80.51%
Oper. Margin-1215.31%
EBITDA Margin0.00%
Profit Margin-99.58%
ROE-6.46%
ROA-2.87%
Growth
Revenue Growth-3.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-8.07M USD
CapEx (TTM)27.00K USD
FCF Margin-635.95%
FCF Yield-80.65%
Net Debt-5.14M USD
Net Debt/EBITDA0.42
Balance Sheet
Debt/Equity0.56
Current Ratio1.20
Quick Ratio1.01
Book Value/Sh3.00 USD
Cash/Share2.99 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJul 15, 2019
Splits
Last Split1:40
Split DateJan 30, 2025
Analyst Consensus
Rating—
Target (Mean)22.00 USD
Upside (mean)+897.7%
Target Range18.00 USD – 26.00 USD
18.00+897.7% to mean26.00
# Analysts2
Ownership
Shares Out.4.98M
Float4.14M
Insiders3.43%
Institutions1.34%
Short Interest
Short Ratio5.2d
Short % Float3.01%
Short % Out.3.01%
Shares Short145.80K
Short (prev mo.)134.58K
Technical
SMA 502.633 (-16.3%)
SMA 2002.814 (-21.6%)
Beta0.70
S&P 52W Chg16.45%
Avg Vol (30d)16.36K
Avg Vol (10d)15.32K
Technical Indicators
RSI (14)32.7
MACD-0.1104
MACD Signal-0.0954
MACD Hist.-0.0150
BB Upper2.667 USD
BB Middle2.446 USD
BB Lower2.225 USD
BB Width18.05%
ATR (14)0.1443 USD
Vol Ratio (20d)1.78x